188Re-P2045

**188Re-P2045** is a radiopharmaceutical composed of an 11-amino acid somatostatin peptide analogue conjugated to the beta-emitting radionuclide rhenium-188. It is designed to target somatostatin receptors, particularly subtype SSTR2, which are highly expressed in various neuroendocrine tumors and pancreatic cancers. Upon binding to its receptor, the compound is internalized, enabling localized delivery of beta radiation that induces tumor cell death primarily through DNA damage. The drug has received Orphan Drug Designation by the FDA for pancreatic cancer. Early-phase clinical trials have also explored its use in small cell lung cancer, with preclinical data supporting antitumor activity and selectivity.

Brand names

Tozaride

Other names

Rhenium-188 P2045Rhenium188 P2045Rhenium 188 P2045Re-188-P2045Re188-P2045Re 188-P2045